Indications and uses
■ Helps temporarily relieves the symptoms of: ■ stiffness ■ pain in limbs, joints or legs ■ cramps in calves, feet or legs
Leg Cramps
- Manufacturer
- Hyland's Consumer Health Inc.
- Effective date
- 2026-08-17
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 15
- Source
- daily-update
- Hydrated at
- 2026-08-20 01:00:57
Label at a glance#
ProductLEG CRAMPS
Active ingredientCINCHONA OFFICINALIS BARK, ACONITUM NAPELLUS, PSEUDOGNAPHALIUM OBTUSIFOLIUM, LEDUM PALUSTRE TWIG, MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE, TOXICODENDRON PUBESCENS LEAF, VISCUM ALBUM FRUITING TOP
Label structure10 sections
Dosage and administration
■ Use as directed. Adults and children 12 years and over Dissolve 2–3 tablets under tongue every 4 hours as needed. If the initial dosage is not providing immediate relief, dissolve 2–3 tablets under tongue every 15 minutes until relieved, up to 6 doses. Children under 12 years of age Ask a doctor before use.
Contacts and useful links#
Websitewww.hylands.com
www.hylands.com
www.hylands.comLabel contents#
Full prescribing information#
OTC - PURPOSE SECTION
Temporarily relieves symptoms of: stiffness, pain in limbs, joints or legs, cramps in calves, feet or legs
Drug Facts
Active ingredients
Active ingredients | Purpose |
Aconitum Napellus 6X HPUS | pains in joints and legs |
Cinchona Officinalis 3X HPUS | pains in limbs and joints; cramping in legs |
Gnaphalium Polycephalum 3X HPUS | cramps in calves and feet |
Ledum Palustre 6X HPUS | pain and cramps in legs |
Magnesia Phosphorica 6X HPUS | muscle cramps |
Rhus Toxicodendron 6X HPUS | pain and stiffness |
Viscum Album 3X HPUS | pains in joints |
“HPUS” indicates that the active ingredients are in the official Homeopathic Pharmacopoeia of the United States.
Uses
■ Helps temporarily relieves the symptoms of:
■ stiffness ■ pain in limbs, joints or legs ■ cramps in calves, feet or legs
Warnings
Ask a doctor before use if you are
sensitive to quinine.
Stop use and ask a doctor
if symptoms persist for more than 7 days or worsen.
If pregnant or breastfeeding
Ask a health professional before use.
Keep out of reach of children
Directions
■ Use as directed.
| Adults and children
12 years and over | Dissolve 2–3 tablets under tongue every 4 hours as needed. If the
initial dosage is not providing immediate relief, dissolve 2–3 tablets under tongue every 15 minutes until relieved, up to 6 doses. |
| Children under
12 years of age | Ask a doctor before use. |
Inactive ingredients
Acacia Gum, Lactose.
Questions?
www.hylands.com or care@hylands.com
Indications and Usage Dosage and Administration
Uses
- Temporarily relieves the symptoms of:
- stiffness
- pain in limbs, joints or legs
- cramps in calves, feet or legs
Directions
■ Temporarily relieves the symptoms of: ■ stiffness ■ pains in limbs ■ joints or legs ■ cramps in calves ■ feet or legs
Adults and children 12 years and over | Dissolve 2–3 tablets under tongue every 4 hours. If the initial dosage is not providing relief, dissolve 2–3 tablets under tongue every 15 minutes, up to 6 doses. |
Under 12 years of age | Consult a physician. |
PRINCIPAL DISPLAY PANEL, Hyland's Leg Cramps Tablets 50 Count
Leg Cramps 50 Tablets
PRINCIPAL DISPLAY PANEL, Hyland's Leg Cramps Tablets 100 Count
Hyland's
LEG
CRAMPS
FAST + EFFECTIVE RELIEF*
100
QUICK-DISSOLVING
TABLETS
HOMEOPATHIC
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 54973-2956-2 | EA - Each | 54973-2956 | d6241c8d-4ee8-4cac-a2bf-b5a7ba88bc1f | 1 | 2020-05-08 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACONITUM NAPELLUS | ACTIVE INGREDIENT | U0NQ8555JD | 1 | |
| CINCHONA OFFICINALIS BARK | ACTIVE INGREDIENT | S003A158SB | 1 | |
| LEDUM PALUSTRE TWIG | ACTIVE INGREDIENT | 877L01IZ0P | 1 | |
| MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE | ACTIVE INGREDIENT | HF539G9L3Q | 1 | |
| PSEUDOGNAPHALIUM OBTUSIFOLIUM | ACTIVE INGREDIENT | 36XQ854NWW | 1 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE INGREDIENT | 6IO182RP7A | 1 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE INGREDIENT | BK9092J5MP | 1 | |
| ACONITUM NAPELLUS | ACTIVE MOIETY | U0NQ8555JD | 1 | |
| CINCHONA OFFICINALIS BARK | ACTIVE MOIETY | S003A158SB | 1 | |
| LEDUM PALUSTRE TWIG | ACTIVE MOIETY | 877L01IZ0P | 1 | |
| MAGNESIUM CATION | ACTIVE MOIETY | T6V3LHY838 | 1 | |
| PSEUDOGNAPHALIUM OBTUSIFOLIUM | ACTIVE MOIETY | 36XQ854NWW | 1 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE MOIETY | 6IO182RP7A | 1 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE MOIETY | BK9092J5MP | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Products#
Every source-derived product name is available through these pages.
- LEG CRAMPS
- cinchona officinalis bark, aconitum napellus, pseudognaphalium obtusifolium, ledum palustre twig, magnesium phosphate, dibasic trihydrate, toxicodendron pubescens leaf, and viscum album fruiting top
- CINCHONA OFFICINALIS BARK
- ACONITUM NAPELLUS
- PSEUDOGNAPHALIUM OBTUSIFOLIUM
- LEDUM PALUSTRE TWIG
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE
- MAGNESIUM CATION
- TOXICODENDRON PUBESCENS LEAF
- VISCUM ALBUM FRUITING TOP
- LACTOSE
- ACACIA
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 54973-2956 | 54973-2956-1, 54973-2956-3, 54973-2956-2, 54973-2956-4, 54973-2956-6 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CINCHONA OFFICINALIS BARK | S003A158SB | ACTIB |
| ACONITUM NAPELLUS | U0NQ8555JD | ACTIB |
| PSEUDOGNAPHALIUM OBTUSIFOLIUM | 36XQ854NWW | ACTIB |
| LEDUM PALUSTRE TWIG | 877L01IZ0P | ACTIB |
| MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE | HF539G9L3Q | ACTIB |
| TOXICODENDRON PUBESCENS LEAF | 6IO182RP7A | ACTIB |
| VISCUM ALBUM FRUITING TOP | BK9092J5MP | ACTIB |
| LACTOSE | J2B2A4N98G | IACT |
| ACACIA | 5C5403N26O | IACT |
Source Document#
Older Hydrated Versions#
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 14 | 2024-10-23 | full-release | 2026-06-01 02:28:21 |
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| LEG CRAMPS | CINCHONA OFFICINALIS BARK, ACONITUM NAPELLUS, PSEUDOGNAPHALIUM OBTUSIFOLIUM, LEDUM PALUSTRE TWIG, MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE, TOXICODENDRON PUBESCENS LEAF, AND VISCUM ALBUM FRUITING TOP | Hyland's Consumer Health Inc. | 53425c3b-6117-475c-bd8c-08f05b452078 | 2026-08-17 | Warnings | 54973-2956-1 54973-2956-4 54973-2956-6 54973-2956-2 54973-2956-3 54973-2956 54973295603 54973295604 54973295606 54973295601 54973295602 59465986-21d6-30f8-e063-6294a90aceaa 53425c3b-6117-475c-bd8c-08f05b452078 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.